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The recent implementation of genomic and lipidomic approaches has produced a large body of evidence
implicating the sphingolipid ceramide in a diverse range of physiological processes and as a critical
modulator of cellular stress. In this review, we discuss from a historical perspective the most important
discoveries produced over the last decade supporting a role for ceramide and its metabolites in the patho-
genesis of insulin resistance and other obesity-associated metabolic diseases. Moreover, we describe how
a ceramide-centric view of insulin resistancemight be reconciled in the context of other prominent models of
nutrient-induced insulin resistance.Introduction
In 2002, Yusuf Hannun and Lina Obeid penned a review article
entitled ‘‘The Ceramide-Centric Universe of Lipid-Mediated
Cell Regulation: Stress Encounters of the Lipid Kind’’ (Hannun
andObeid, 2002). The authors noted how advances in lipidomics
(i.e., the implementation of mass spectroscopy to quantify
lipid species) and genomics (i.e., the cloning of the majority of
genes involved in sphingolipid synthesis and degradation) had
provided new tools to probe into ceramide function, and that
the implementation of such approaches was revealing a potent
role for sphingolipids in generalized cellular responses to stress.
Indeed, virtually all stress stimuli (e.g., chemotherapeutics,
inflammatory agonists, saturated fatty acids, etc.) had by that
time been shown to increase rates of ceramide synthesis.
Moreover, functional studies in cultured cells were revealing
that the lipid had profound effects on cell survival and metabo-
lism. In the years that followed that review, an explosion of
published reports using both in vitro and in vivo model systems
implicated ceramide accumulation in the pathogenesis of
multiple diseases associated with obesity,y including diabetes,
cardiomyopathy, and atherosclerosis (Holland and Summers,
2008). Of relevance to this review series, ceramide was shown
to contribute to insulin resistance, a metabolic state that
places individuals at risk for diabetes and cardiovascular disease
(Reaven, 1988).
In this article, we aim to provide a historical perspective of the
seminal studies implicating ceramides in insulin resistance and
metabolic disease. Moreover, we will discuss how a ceramide-
centric view of insulin resistance can be reconciled with other
avenues of research linking nutrient oversupply and insulin
sensitivity.
A Brief Historical Timeline of Studies Relating
Ceramides, Glucosylceramides, and Insulin Resistance
In comparison to the research tools that are available to sphingo-
lipidologists today, approaches for studying sphingolipids in
prior decades were somewhat lacking. For example, ceramide
quantification most frequently involved a tedious ‘‘diacylgly-
cerol-kinase assay’’ that was viewed by some as not quantita-
tively reliable. Moreover, this approach is not able to distinguishceramides from dihydroceramides or provide information on
distinct ceramide species. Another limiting factor was the over-
reliance of scientists upon exogenous, water-soluble ceramide
analogs comprised of a very short acyl chain. These compounds
are easy to use experimentally, but have detergent-like proper-
ties and were often added at nonphysiological concentrations.
Both of these approaches generated a fair bit of concern that
biological actions being attributed to the lipid were artifactual
in nature (Hofmann and Dixit, 1998; van Blitterswijk et al.,
2003). As predicted by Drs. Obeid and Hannun, the advent of
lipidomics and genomics allowed for a far more sophisticated
analysis of ceramides in cell function. The implementation of
these approaches, both in vitro and in vivo, has produced a large
body of data implicated ceramide and its metabolites in insulin
resistance and metabolic disease. Key discoveries in this area
during the last decade include the following:
 Studies using cultured cells and isolated muscles revealed
that endogenous ceramides and glucosylceramides antag-
onize insulin-stimulated glucose uptake and anabolism,
and thus could mimic the effects of exogenous sphingoli-
pid analogs.
 Studies in rodentmodels of obesity revealed that genetic or
pharmacological inhibition of ceramide or glucosylcera-
mide biosynthesis is insulin sensitizing.
 Studies in rodents revealed that inhibition of ceramide
or glucosylceramide biosynthesis also warded off several
pathologies associated with insulin resistance including
diabetes, atherosclerosis, hepatic steatosis, and/or cardio-
myopathy.
 Studies in cultured cells provided a wealth of mechanistic
data about how ceramide impairs insulin signaling.
 Studies applying quantitative lipidomics revealed inverse
relationships between ceramide and glucosylceramide
levels and insulin sensitivity in both rodents and humans.
 Studies identified strong relationships between inflamma-
tory events, ceramide biosynthesis, and insulin resistance.
 Studies revealed roles for adipokines (e.g., leptin, adipo-
nectin, and tumor necrosis factor alpha) in the modulation
of cellular ceramide levels.Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 585
Figure 1. Schematic Timeline of the Seminal
Studies Supporting a Role for Ceramides in
Insulin Resistance and Metabolic Disease
A large body of literature has accumulated over the
past two decades implicating the sphingolipid
ceramide and its metabolites in the development
of insulin resistance and its associated co-
morbidities.
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The net result of these findings is that ceramide is now appreci-
ated as an important nutrient metabolite that accumulates in
obesity, altering cellular metabolism and promoting apoptosis,
and thus giving rise to many of the hallmark events associated
with metabolic disease. These data suggest that inhibitors of
ceramide synthesis or activators of ceramide degradation may
prove efficacious as therapeutics to combat insulin resistance
and metabolic disease.
Cell Culture and Isolated Tissue Studies on Ceramides,
Glucosylceramides, and Insulin Resistance
As described above, the first studies evaluating ceramide effects
on insulin action involved the use of ceramide analogs that can
be added directly to the media bathing cultured cells or isolated
tissues without conjugating to carrier proteins. In cultured
adipocytes and/or isolated skeletal muscle, these ceramide
analogs inhibit insulin-stimulated glucose uptake by blocking
translocation of the GLUT4 glucose transporter, as well as
glycogen synthesis (Hajduch et al., 2001; Summers et al.,
1998; Wang et al., 1998). These effects appear to result from
ceramide’s ability to block activation of Akt/PKB, a serine/
threonine kinase that is obligate for insulin and growth-factor586 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.activation of anabolism and cell survival.
Overexpression of constitutively active
Akt/PKB negates their effects on either
apoptosis or glucose uptake (Summers
et al., 1998).
Though early reports suggested that
ceramide inhibited insulin activation of
upstream signaling events (i.e., activation
of phosphatidylinositol 3 kinase, which is
required for Akt/PKB activation) (Kanety
et al., 1996; Peraldi et al., 1996), the
majority of studies found no such relation-
ship (Chavez et al., 2003; Hajduch et al.,
2001; Kralik et al., 2002; Summers et al.,
1998; Teruel et al., 2001; Wang et al.,
1998). In all cell types tested, however,
ceramide blocks activation of Akt/PKB
(Chavez et al., 2003; Powell et al., 2003;
Salinas et al., 2000; Stratford et al.,
2001; Stratford et al., 2004; Teruel et al.,
2001; Zinda et al., 2001). This regulatory
event is accomplished by at least two
mechanisms (Figure 2):
 First, ceramide blocks the translo-
cation of Akt/PKB to the plasma
membrane (Stratford et al., 2001).The Hundal group found that this results from the phos-
phorylation of Akt/PKB on a regulatory site in the enzyme’s
PH domain, lowering its affinity for phosphoinositides
(Powell et al., 2003). The key intermediate here is the
atypical PKC isoform protein kinase Cz, which is activated
by ceramide in vitro (Bourbon et al., 2000). Expression of
an Akt/PKB isoform with the S34 site converted to an
alanine confers resistance to ceramide in cultured myo-
tubes. Similar findings were obtained in vascular smooth
muscle (Bourbon et al., 2002; Fox et al., 2007), where it
was further demonstrated that ceramide stabilized interac-
tions between Akt/PKB and PKCz by recruiting the
enzymes to detergent-resistant membrane fractions (e.g.,
membrane rafts or caveolae) (Fox et al., 2007; Hajduch
et al., 2008).
 The secondmechanism involves that dephosphorylation of
Akt/PKB by protein phosphatase 2A (Chavez et al., 2003;
Salinas et al., 2000; Teruel et al., 2001; Zinda et al.,
2001). Addition of okadaic acid or overexpression of the
SV40 small T antigen, both of which inhibit PP2A, prevents
the effects of ceramide on Akt/PKB in a number of different
cell types (Chavez et al., 2003; Salinas et al., 2000; Teruel
et al., 2001; Zinda et al., 2001).
Figure 2. Schematic Diagram Depicting the
Multiple mechanisms by which Ceramide Is
Generated in Response to Stress Stimuli
Ceramide is generated in response to virtually all
stress stimuli including those associated with
obesity (e.g., chemotherapeutics, inflammatory
agonists, saturated fatty acids, etc.). Cellular ce-
ramide can be formed (1) by a de novo biosyn-
thesis from precursor palmitate; (2) through the
activation of inflammatory pathways triggered by
TLR4 recognition of saturated fatty acids, which
induce the upregulation of genes driving ceramide
biosynthesis; (3) through the breakdown of more-
complex sphingolipids as part of a ‘‘salvage
pathway’’; and (4) through the disruption of endo-
plasmic reticulum homeostasis (ER stress). The
aberrant accumulation of ceramidemay lead to the
activation of several signaling and putative targets
that may impair normal cellular function, including
insulin action. For instance, it has been shown that
ceramide (a) directly activates PKCz isoformwhich
phosphorylates and inhibits the translocation of
Akt/PKB; (b) stimulates the activity of a cytosolic
protein phosphatase 2A (PP2A), the primary
phosphatase responsible for dephosphorylating
Akt/PKB; and (c) induce further ER stress and
mitochondrial dysfunction. Once generated, ce-
ramide can be metabolized to give rise to a broad
array of sphingolipid-derived molecules that may
have different effects on cellular function. The
insulin sensitizer adiponectin modulates ceramide
metabolism via an intrinsic ceramidase activity of
its two receptors, AdipoR1 and AdipoR2, thus
depleting cells of ceramide and converting it
sphingosine, ultimately inducing the formation of
the prosurvival factor sphingosine 1-phosphate. DAG produced from polyunsaturated fatty acids (i.e., linoleate) is a potent stimulator PKC isoforms (e.g., PKCq).
This activation was associated with amarkedly increment of serine/threonine phosphorylation of IRS-1, a phenomenon that has been shown to reduce its insulin-
stimulated tyrosine phosphorylation and downstream propagation of the insulin signaling pathway.
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2006; Stratford et al., 2004), while in other cultured cell systems
either PP2A or PKCz plays the dominant role (Bourbon et al.,
2002; Chavez et al., 2003; Fox et al., 2007). Blouin et al. (2010)
proposed that the key determinant of which pathway was domi-
nant in a certain cell type is the relative abundance of caveolae.
As described above, the reliance of the majority of these
studies on the water-soluble ceramides cast doubt on the phys-
iological relevance of the ceramide-Akt/PKB relationship.
However, subsequent studies revealed that small increases in
endogenous ceramide (50%) were sufficient to inhibit Akt/
PKB. Themodel systemmost abundantly utilizedwas developed
by Schmitz-Peiffer and Trevor Biden, who demonstrated
that exposing cultured myotubes to exogenous palmitate, the
most abundant saturated fatty acid in the circulation, increased
ceramide accumulation while simultaneously inhibiting Akt/
PKB (Schmitz-Peiffer et al., 1999) (Figure 2). The authors
concluded that ceramide was the likely intermediate accounting
for the antagonism of insulin signaling. Subsequent studies re-
vealed that ceramide was obligate. Using model systems similar
to this one, scientists subsequently demonstrated that this
increase in endogenous ceramide biosynthesis was requisite
for the palmitate effect, as pharmacological inhibition or
small interfering RNA (siRNA)-mediated knockdown of enzymes
required for ceramide biosynthesis (i.e., serine palmitoyltrans-
ferase, ceramide synthases, or dihydroceramide desaturase)
completely blocked the palmitate effects on insulin signaling
(Chavez et al., 2003; Holland et al., 2011a; Hu et al., 2011; Powellet al., 2003, 2004; Watson et al., 2009). Subsequent studies
shown that these approaches also prevented palmitate-antago-
nism of glucose uptake in isolated soleus muscle preparations
from rodents (Holland et al., 2007b) or humans (Thrush et al.,
2011).
As an alternative strategy for manipulating endogenous
ceramide, we found that blocking rates of ceramide metabolism
increased endogenous ceramide levels while blocking activation
of Akt/PKB. Specifically, treatment of cultured myotubes
with inhibitors of acid ceramidase, which converts ceramide
into sphingosine, or glucosylceramide synthase, which converts
ceramide into glucosylceramide, exacerbated palmitate-in-
duced insulin resistance (Chavez et al., 2005). Conversely, over-
expression of acid ceramidase fully negated the inhibitory effects
of palmitate on insulin signaling (Chavez et al., 2003; Powell
et al., 2004). These studies confirmed the requirement for ceram-
ide, rather than another sphingolipid metabolite, in the inhibition
of Akt/PKB in muscle.
Glucosylceramide is the precursor for a complex family of
gangliosides. Unlike cultured myotubes, where glucosylcera-
mides are without effect (J.A.C. and S.A.S., unpublished data),
adipocytes are highly sensitive to glucosylated sphingolipids.
For example, exogenous GM3 ganglioside inhibits insulin
activation of the insulin receptor substrate-1, the first step in
signaling cascade linking the hormone to anabolism (Aerts
et al., 2007a; Tagami et al., 2002). Moreover, the inflammatory
cytokine tumor necrosis factor alpha (TNFa) induces GM3 accu-
mulation in lipid rafts, and the antagonistic effects of the TNFaCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 587
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(Inokuchi, 2006; Kabayama et al., 2005). The mechanism
appears to involve the dissociation of insulin receptors from
caveolin-1, thus uncoupling them from its downstream signaling
effectors (Kabayama et al., 2007). As described below, sub-
sequent in vivo studies confirmed roles for glucosylated ceram-
ides in insulin resistance, adipose inflammation, and hepatic
steatosis.
Studies Investigating the Role of Ceramides and
Glucosylceramides in Insulin Resistance in Rodents
Manipulation of enzymes controlling sphingolipid synthesis or
degradation in mice has a potent effect on insulin resistance
and ameliorates lipotoxic responses associated with obesity
(Holland and Summers, 2008). The workhorse reagent for
these studies is myriocin, a specific inhibitor of serine palmitoyl-
transferase (SPT), the first and rate-limiting enzyme in the de
novo synthesis pathway that converts palmitoyl-CoA and serine
into ceramides (Figure 2). Myriocin can be administered
chronically to both rats and mice, and it appears to be well toler-
ated. In rodent models of obesity or other aspects of metabolic
disease, myriocin prevents insulin resistance and diabetes
(Frangioudakis et al., 2010; Holland et al., 2007a; Ussher et al.,
2010; Yang et al., 2009a), atherosclerosis (Glaros et al., 2008;
Hojjati et al., 2005; Park et al., 2004, 2008b), and cardiomyop-
athy (Park et al., 2007, 2008a). Myriocin was originally isolated
from an extract of the fruiting bodies of the fungus Isaria sinclairii
(辛克莱棒束孢) and its parasitic host larva, and has since been
identified as a common component in a number of closely
related fungal species (e.g., Cordyceps sinensis, Cordyceps
cicadea, and Cordyceps sinclairii) (Wang et al., 2009; Yu et al.,
2009). Extracts from these species are commonly used in tradi-
tional Chinese medicine as a treatment for a plethora of condi-
tions, including diabetes, due to their ability to induce an ‘‘eternal
youth’’ nostrum. When given to rats, extracts of these agents
improve glucose tolerance and insulin sensitivity (Lo et al.,
2004, 2006; Paterson, 2008) and ameliorate hypertension (Hollo-
way et al., 2009).
These in vivo studies evaluating the role of ceramide in insulin
resistance and diabetes have crossed over a large subset of
animal models including the following: high fat-fed mice, ob/ob
mice, lipid-infused rats, dexamethasone-treated rats and mice,
Zucker fa/fa rats, and ZDF rats (Frangioudakis et al., 2010;
Holland et al., 2007a; Turinsky et al., 1990; Yang et al., 2009b).
Hyperinsulinemic-euglycemic clamp studies confirm that myrio-
cin improves insulin sensitivity in both muscle and the liver in
these models (Holland et al., 2007a). In the ZDF rats, SPT inhibi-
tion additionally preserved pancreatic insulin (William L. Holland
and S.A.S., unpublished data) and prevented the onset of frank
diabetes (Holland et al., 2007a), confirming studies done by the
Unger laboratory using another, albeit less specific, inhibitor
SPT inhibitor, cycloserine (Shimabukuro et al., 1998).
Though these findings universally support the enzyme’s role in
insulin sensitivity in both skeletal muscle and liver, some impor-
tant differences emerge that warrant elucidation. The relative
effects of myriocin on body weight are unclear, and some
discrepancies in the literature exist. Two groups, including
ours, found that the insulin-sensitizing effects of myriocin were
independent of changes in body weight or a reduction in obesity588 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.(Holland et al., 2007a; Ussher et al., 2010). Moreover, in apolipo-
protein-E-deficient mice (ApoE/) fed a high-fat diet (discussed
below), myriocin also had only a minor impact on body weight
(Glaros et al., 2008). However, in a subsequent study using
high fat-fed and ob/ob mice, myriocin reduced body weight
(Yang et al., 2009b). These are important differences that have
profound implications on our understanding of the mechanism
of sphingolipid action.
Haploinsufficiency for the SPT subunit SPTLC2 and for dihy-
droceramide desaturase-1 (Des1), both of which are requisite
for ceramide biosynthesis, is also insulin sensitizing. Mice
heterozygous for SPTLC2 demonstrate reduced peripheral
ceramide levels and an improvement in insulin sensitivity after
high-fat feeding (Li et al., 2011). Similarly, heterozygous
Des1+/ mice are protected from dexamethasone-induced
insulin resistance (Holland et al., 2007a).
Asmentioned, several laboratories have established a correla-
tion between diets rich in saturated fatty acids with ceramide
accumulation and whole-body insulin sensitivity in animals
(Blachnio-Zabielska et al., 2010; Frangioudakis et al., 2010;
Holland et al., 2007a; Lee et al., 2006). However, to the authors’
knowledge, a direct comparison of different saturated fatty acids
in the high-fat diet composition with corresponding effects in
systemic or tissue ceramide levels and insulin sensitivity is
missing.
In mammals, a large family of (dihydro)ceramide synthase
(CerS) isoforms exists (these catalyze the acylation of sphinga-
nine to produce dihydroceramide) (Figure 2). At least six genes
that encode CerS have been cloned and characterized (Pewz-
ner-Jung et al., 2006). Biochemically, individual CerS isoforms
show substrate preference for specific chain length fatty acyl-
CoAs, thus generating distinct ceramides with distinct acyl
chain lengths. Frangioudakis et al. have recently demonstrated
that the expression of CerS1, the most abundant isoform in
skeletal muscle involved primarily in the synthesis of C18:0
ceramides, was significantly increased in mice fed a high-fat
diet and that this change was associated with alterations in
ceramide levels and glucose tolerance (Frangioudakis et al.,
2010). However, a detailed study of all ceramide subspecies
derived from each CerS isoforms and their implication in the
development of insulin resistance has not yet been confirmed
through experimentation.
Regarding the glucosylated ceramides discussed above,
rodent studies strongly support a role of these metabolites in
insulin resistance. First, obesity is associated with enrichment
in gangliosides in adipose tissue, as in C57BL/6J, KK, and
KKAy mice obesity increases levels of the complex gangliosides
GM2, GM1, and GD1a. Second, mice lacking GM3 synthase,
which generates the major ganglioside precursor, are protected
from insulin resistance and glucose intolerance caused by high-
fat feeding (Yamashita et al., 2003). Third, a new generation
of highly specific glucosylceramide synthase inhibitors have
been shown to improve glucose tolerance and increase insulin
sensitivity in muscle and liver of ob/ob and DIO mice and ZDF
rats, as well as to prevent steatosis and adipose inflammation
(Aerts et al., 2007a, 2007b; Bijl et al., 2008, 2009; van Eijk
et al., 2009; Zhao et al., 2007, 2009). Collectively, these data
strongly suggest that glucosylated ceramides contribute to
insulin resistance.
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in Muscle Insulin Resistance
Dietary experiments on healthy human subjects to evaluate the
effect of high-fat diet enriched with saturated fatty acid (i.e.,
palmitate) on insulin sensitivity are still lacking. However, since
palmitate is the most abundant saturated fatty acid in the diet,
we can assume that this experimental approach occurs naturally
during obesity. In fact, the associated accruement of ceramides
in peripheral tissues of obese insulin resistance subjects has
been well documented (Adams et al., 2004). Most studies have
been conducted in skeletal muscle (discussed here), though
relationships between obesity and ceramide have also been
observed in plasma (de Mello et al., 2009; Gill and Sattar,
2009; Haus et al., 2009) and fat (Kolak et al., 2007).
In 2004, Mandarino and colleagues obtained skeletal muscle
biopsies from individuals that had undergone a hyperinsuline-
mic-euglycemic clamp. In this study, total ceramide levels
were increased by nearly 2-fold in obese insulin-resistant
subjects, and that this was accompanied by a significant reduc-
tion in levels of activated Akt/PKB (Adams et al., 2004). In
a similar study, Straczkowski et al. performed lipid infusions in
human subjects and found a significant negative correlation
between ceramide content in skeletal muscle and insulin sensi-
tivity (Straczkowski et al., 2004). A number of subsequent studies
demonstrated relationships between muscle ceramide and
insulin resistance (Amati et al., 2011; Dube´ et al., 2008; Schenk
and Horowitz, 2007; Straczkowski et al., 2004, 2007). These
observations were further corroborated by interventional studies
showing that chronic (Amati et al., 2011; Dube´ et al., 2008) or
acute (Schenk and Horowitz, 2007) exercise lowered ceramide
content in conjunction with an improvement in insulin sensitivity,
perhaps by directing lipids into the triglyceride pool. The latter
hypothesis is based on recent data obtained by Amati et al.
demonstrating that the exercise-induced ceramide reduction
was accompanied by an upregulation of several proteins associ-
ated with lipid droplet esterification, lipolysis, and oxidation
(Amati et al., 2011). In some of these studies, the relationship
between ceramide and insulin resistance was in evidence, while
a relationship between other lipid species (triglycerides, diacyl-
glycerols) was not supported (Amati et al., 2011; Coen et al.,
2010).
To date, no interventional studies have been done on human
subjects to evaluate whether pharmacological inhibition of
sphingolipid synthesis alters insulin sensitivity.
In contrast to these studies positively associating muscle
ceramide with human insulin resistance, some studies have
failed to observe such a relationship. For example, Helge and
colleagues have consistently observed no relationship between
muscle ceramide and insulin sensitivity (Helge et al., 2011a,
2012b; Skovbro et al., 2008). Moreover, Dube´ et al. (2011) found
that while exercise-induced weight loss improved insulin sensi-
tivity concomitant with a reduction in ceramide, diet-induced
weight loss negated insulin resistance without lowering muscle
ceramides.
Relationship with Other Models of Nutrient-Induced
Insulin Resistance
As will be revealed in this series of review articles, a number
of other intracellular intermediates associated with nutrientoversupply have been shown to antagonize insulin action.
Importantly, the mechanisms put forth herein and in these other
articles are not mutually exclusive, and one would predict that
tissues have evolved multiple mechanisms to gauge nutrient
status and fuel needs. Indeed, the idea that multiple different
nutrient metabolites would alter insulin sensitivity seems not
only plausible, but likely. From a personalizedmedicine perspec-
tive, the relative importance of these different nutritional cues
would likely have differing levels of importance in distinct
subsets of individuals. Nonetheless, careful review of the litera-
ture reveals some interesting areas of overlap between the
‘‘ceramide hypothesis’’ and with other nutrient metabolites.
Herein we will discuss how a role for ceramide can be reconciled
with some of the other pathways discussed in this review series.
Ceramides and Inflammation
Obesity has long been known to associate with a low-grade
inflammatory state. One mechanism for this involves the activa-
tion of toll-like receptors (TLRs), which induce the transcription of
inflammatory cytokines such as TNFa and interleukin-6 (IL6), by
saturated fats (Senn, 2006; Shi et al., 2006; Tsukumo et al.,
2007). In an elegant series of studies utilizing lipid infusion strat-
egies in TLR4 knockout mice, the Flier group demonstrated the
following: (1) saturated fats selectively activate TLRs, (2) TLRs
are requisite for lipid induction of TNFa and other cytokines,
and (3) knockout mice lacking TLRs are protected from lipid-
induced insulin resistance (Shi et al., 2006). TLRs signal through
IkKb and NFkB, and the Shoelson group has identified this
pathway as an important contributor to impaired glucose toler-
ance (Cai et al., 2005; Donath and Shoelson, 2011; Kim et al.,
2001; Yuan et al., 2001).
Through the Lipidmaps initiative (http://www.lipidmaps.org),
the Merrill group conducted a broad lipidomic profile of cells
treated with LPS, a TLR4 agonist. TLR4 activation selectively
and strongly increases sphingolipid levels within the cell (Sims
et al., 2010). These data suggested that ceramide may be an
important effector of TLR4-induced insulin resistance (Figure 2).
As demonstrated in Holland et al. (2011a), recent studies
revealed that ceramide is indeed an obligate intermediate linking
TLR4 to the induction of insulin resistance, both in vitro and
in vivo. Moreover, studies in two different patient populations
revealed particularly strong correlations between plasma ceram-
ides, circulating cytokines, and insulin resistance (de Mello
et al., 2009; Gill and Sattar, 2009; Haus et al., 2009). These
data place palmitate, TLR4, and ceramide on a linear pathway
that modulates insulin sensitivity (Figure 1).
Ceramides and Mitochondrial Stress
Mitochondrial abnormalities have been seen in some popula-
tions of insulin resistance, and the impairment in mitochondrial
function has been identified as either a cause or a consequence
of the condition (Kraegen et al., 2008; Turner and Heilbronn,
2008). One hypothesis put forth is that the impairment in mito-
chondrial lipid oxidation leads to the buildup of toxic lipids
such as ceramide or diacylglycerol (Bruce et al., 2009). A second
idea is that increased flow of nutrients through mitochondrial
promotes incomplete fatty acid oxidation and/or oxidative
stress, leading to a compensatory impairment in glucose utiliza-
tion (Koves et al., 2008). Important evidence for this hypothesis
involves manipulation of intracellular levels of malonyl-CoA,
which inhibits lipid import intomitochondria by blocking carnitineCell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc. 589
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boxylase (MCD), which leads to the accumulation of malonyl-
CoA, increases rates of glucose utilization in vitro (Bouzakri
et al., 2008) and in vivo (Koves et al., 2008).
Surprisingly, MCD depletion was associated with a reduction
of ceramides (Ussher et al., 2010). One possible explanation
for this observation is that the import of acyl-CoAs into the inner
mitochondrial membranemay be important for producing partic-
ular pools of ceramide, as most of the de novo synthesis have
been found on mitochondrial membranes (Bionda et al., 2004;
Shimeno et al., 1998). The question then emerges as whether
ceramide produced within the organelle could contribute to
mitochondrial stress. Depleting ceramides with myriocin in
mice fed a high-fat diet improves mitochondrial performance
as evidenced by increases in oxygen consumption, increased
citrate synthase activity, and preservation of PGC1 expression
(Schmitz-Peiffer, 2010; Ussher et al., 2010). The effects of
myriocin on lipid oxidation were unclear; long-chain acylcarni-
tines were increased, suggesting incomplete lipid oxidation,
but short-chain acylcarnitines were reduced. Studies in cell
culture are also suggestive of roles in mitochondrial stress.
As we have reviewed elsewhere, ceramide alters membrane
permeability, inhibits electron transport chain intermediates,
and promotes oxidative stress (Bikman and Summers, 2011). A
full discussion of these myriad actions is beyond the scope of
this review, but these findings are generally consistent with
idea that the ‘‘mitochondrial stress’’ and ‘‘ceramide’’ hypotheses
are compatible (Figure 2).
Ceramides and ER Stress
Endoplasmic reticulum (ER) stress has also been associated
with both b cell apoptosis and peripheral and central insulin
resistance that contribute to diabetes (Cnop et al., 2012). Studies
in b cell lines implicate ceramide as both a cause (Boslem
et al., 2011) and effector (Lei et al., 2010) of ER stress. As satu-
rated fatty acids, but not unsaturated ones, induce ER stress
in muscle and liver, ceramide emerged as a likely candidate
intermediate linking exogenous lipids disruption of ER function
(Figure 2). However, to these authors’ knowledge, the only
study investigating the role of ceramide in ER stress in insulin
sensitive tissues found that inhibitors of ceramide synthesis
did not prevent palmitate-induced ER stress in the liver (Wei
et al., 2006).
Ceramides and Adipokines
Another idea that has gained some attention is that secreta-
gogues coming from adipose tissue are important modulators
of metabolic homeostasis. For example, enlarged adipocytes
show increased secretion of the adipokines leptin, resistin, and
TNFa, all of which have been implicated in insulin resistance.
Moreover, small adipocytes secrete the insulin-sensitizing and
cardioprotective hormone adiponectin. Ceramide is implicated
in the actions of many of these factors.
 Leptin: Ceramide metabolism appears to play a prominent
role in leptin’s central control of feeding. Leptin treatment
decreases arcuate ceramide levels in mice, and the
decrease is important for the hormone’s anorectic actions
(Gao et al., 2011).
 TNFa: The inflammatory cytokine TNFa) induces GM3
accumulation in lipid rafts, and the antagonistic effects of590 Cell Metabolism 15, May 2, 2012 ª2012 Elsevier Inc.the TNFa can be negated by depleting cells of glucosylated
ceramides (Inokuchi, 2006; Kabayama et al., 2005).
 Adiponectin: Adiponectin receptors are homologous to
progestin and adipoQ receptors (PAQR), which were
shown in yeast to mediate their actions by activating a
ceramidase (Holland and Scherer, 2009; Villa et al., 2009).
The homology of these receptors to ceramidase enzymes
suggests that this is an intrinsic part of the molecule, and
ceramidase inhibitors ablate adiponectin receptor activity
(Kupchak et al., 2009). In vivo, Holland et al. recently
demonstrated that adiponectin mediates many of its
actions by activating a ceramidase activity, thus depleting
cells of ceramide and converting it (ultimately) to the pro-
survival factor sphingosine 1-phosphate (Holland et al.,
2011b) (Figure 2).
 Resistin: A role for ceramide in resistin action has not
received much attention. In an isolated muscle system,
resistin was shown to blunt insulin action, but only in the
presence of palmitate (Junkin et al., 2009). This resistin
effect was negated by the inclusion of ceramide synthesis
inhibitors. Surprisingly, however, resistin did not increase
ceramide levels, and in fact decreased levels of these
sphingolipids. Thus, the mechanisms for this interplay are
unclear.
Ceramides and the Brain
Recent findings from numerous groups have established an
essential role for hypothalamic insulin signaling in the mainte-
nance of glucose tolerance (Gelling et al., 2006; Myers et al.,
2009; Obici et al., 2002). Clegg and colleagues demonstrated
that the introduction of saturated fatty acids, but not unsaturated
ones, directly into the brain disrupted insulin signaling to Akt/
PKB in the hypothalamus, altering insulin-regulation of hepatic
glucose output (Benoit et al., 2009). The defect was recapitulated
in animals fed a high-fat diet (Benoit et al., 2009). We recently
found that ceramides accumulate in the hypothalamus of
rodents after lipid infusion or high-fat feeding, suggesting that
the sphingolipid may have a role in hypothalamic insulin resis-
tance under conditions of nutrient oversupply (Holland et al.,
2011a). Thus, while a role for ceramides in the regulation of
insulin action in the brain has not been tested directly, it remains
a formal possibility.
Ceramides versus DAGs
In addition to ceramides, a number of other lipid intermediates
have been suggested to modulate insulin sensitivity. The most
prominent of these is diacylglycerol (DAG), which accumulates
in the obese and has been suggested to activate protein kinase
C (PKC) isoforms that inhibit insulin receptor substrate-1, thus
blocking insulin action (Samuel et al., 2010). In cultured myo-
tubes, isolated rodent muscles, or lipid infused rodents, DAG
did not appear to contribute to saturated fat (i.e., palmitate)-
induced insulin resistance. Indeed, in these model systems,
the administration of ceramide synthesis inhibitors restored
insulin sensitivity in the face of greatly elevated DAG levels
(Chavez et al., 2003; Holland et al., 2007a, 2011a), suggesting
that DAG derived from palmitate is a relatively poor inducer of
insulin resistance. In these model systems, however, the unsat-
urated fatty acid linoleate induced insulin resistance through
a ceramide-independent mechanism (Holland et al., 2007a),
Cell Metabolism
Perspectiveand DAG is a candidate intermediate for this effect (Figure 2). In
fact, infusions of lipid cocktails enriched in linoleate induce
insulin resistance and DAG, but not ceramide (Holland et al.,
2007a; Itani et al., 2002; Yu et al., 2002). Supportive of these
are in vitro experiments showing that unsaturated forms of
DAG are more potent activators of PKCs (Hodgkin et al., 1998;
Wakelam, 1998). These observations have suggested that
DAGmay participate in the regulation of insulin signaling by poly-
unsaturated fatty acids, whereas other derivatives (i.e., ceram-
ides) may be more important for the inhibition of insulin signaling
by saturated fatty acids. However, further studies will be needed
to address these issues.Conclusions
Obeid andHannunwere correct in predicting both the ubiquitous
role of ceramides in mammalian stress responses and the infor-
mation explosion that would result from the cloning of genes
involved in ceramide metabolism and the increased availability
of mass spectroscopy methods to quantify specific ceramide
species. Indeed, the ‘‘advancing crescendo of studies that
have begun to shed significant light on our understanding of
ceramide metabolism and function’’ that they noted in 2002
has shown no signs of diminution. What might not have been
so predictable at the time, however, was how new pharmacolog-
ical approaches and knockout animals would allow for an
assessment of the role of ceramide in vivo, and in turn uncover
roles in obesity and metabolic disease. The redundancy of
approaches utilized to modulate ceramide levels makes it clear
that the sphingolipid and/or one of its metabolites plays a
quantifiably important role in rodent models of obesity. One
can only hope that the rapid pace of progress will ultimately
have a translational impact that provides new therapeutic
options for those suffering from metabolic disease.ACKNOWLEDGMENTS
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